Eli Lilly and Company (LLY)
| Market Cap | 934.14B |
| Revenue (ttm) | 59.42B |
| Net Income (ttm) | 18.41B |
| Shares Out | 895.38M |
| EPS (ttm) | 20.44 |
| PE Ratio | 51.04 |
| Forward PE | 33.78 |
| Dividend | $6.00 (0.58%) |
| Ex-Dividend Date | Nov 14, 2025 |
| Volume | 3,135,742 |
| Open | 1,045.50 |
| Previous Close | 1,049.60 |
| Day's Range | 1,038.25 - 1,057.00 |
| 52-Week Range | 623.78 - 1,057.00 |
| Beta | 0.39 |
| Analysts | Strong Buy |
| Price Target | 1,036.65 (-0.64%) |
| Earnings Date | Oct 30, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $1,036.65, which is a decrease of -0.64% from the latest price.
News
Researchers move closer to matching patients with GLP-1 drug that works best for them
U.S. researchers are beginning to identify clinical characteristics that distinguish “super responders” to GLP-1 weight-loss drugs like Wegovy and Zepbound from patients who lose only moderate amounts...
Lilly announces plans to open Lilly Gateway Labs site in Philadelphia
Gateway Labs model provides lab space and tailored scientific engagement to fuel next-generation medicines New Center City site, in partnership with Breakthrough Properties, will host a select group o...
Eli Lilly Gains from Big Earnings, Bullish Inflows
Eli Lilly and Company (LLY) shares up 15,892% since Big Money bought big in 1990.
Lilly to participate in Citi's 2025 Global Healthcare Conference
INDIANAPOLIS , Nov. 18, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Citi's 2025 Global Healthcare Conference on December 2, 2025. Ilya Yuffa, executive vice president...
Eli Lilly Stock To $1,330?
Eli Lilly's stock (NYSE: LLY) has recently surged 27% over the past month, reaching a current price of $1,022. This rally is fueled by several powerful factors, including robust sales of its weight-lo...
Alger Growth & Income Fund Q3 2025 Portfolio Update
Class A shares of the Alger Growth & Income Fund outperformed the S&P 500 Index during the third quarter of 2025. Apple Inc., Broadcom Inc., and Alphabet Inc. were among the top contributors to perfor...
Eli Lilly weight-loss drug appears to suppress binge-eating signal, small study finds
Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...
Novo Nordisk, Eli Lilly Weight Loss Price War Heats Up. Why It's a Worry for the Stocks.
Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.
Eli Lilly: This Breakout Rally Has More Room To Run
Eli Lilly stock has regained all-time highs, outpacing rivals in the obesity drug market and benefiting from sector rotation into healthcare stocks. LLY's GLP-1 franchise, led by Zepbound and Mounjaro...
Our Top 10 High Growth Dividend Stocks - November 2025
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes
Blood-thinning drugs that doctors often prescribe interchangeably after procedures to reopen narrowed heart arteries don't work equally well in patients with diabetes, a study from India found.
It Looks Like Eli Lilly Will Become The Next Trillion Dollar Baby
Eli Lilly is poised to become the first $1 trillion pharmaceutical company, driven by explosive growth in its weight-loss drug, Mounjaro. LLY's earnings and sales growth have been exceptional, with qu...
Netflix's Stock Split Is Almost Here. Eli Lilly Could Be Next.
The drugmaker's stock checks all the boxes for a split. the price keeps climbing, the company is on fire, and it's a bull market.
Novo Nordisk, Lilly deny partnership with Mangoceuticals on obesity drugs
Novo Nordisk and Eli Lilly do not have a weight-loss drug partnership with telehealth website Mangoceuticals Inc , spokespeople for both companies said, rejecting a press release issued by the company...
Mangoceuticals partners with Lilly, Novo Nordisk to sell weight-loss drugs
Telehealth company Mangoceuticals said on Thursday it has partnered with Eli Lilly and Novo Nordisk to sell the drugmakers' blockbuster weight-loss drugs through its platform.
Bitget Lists LLY, MA, UNH Stock Index Perpetual Futures as Cumulative Trading Volume on Bitget hits $3 Billion
VICTORIA, Seychelles, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bitget, the world's largest Universal Exchange (UEX), has announced the official addition of LLYUSDT, MAUSDT, UNHUSDT stock index perpetual futu...
Is Eli Lilly Stock's Run Too Hot? Here Is How It Can Crash
Eli Lilly stock (NYSE: LLY) has surged by 21% this month, driven by strong third-quarter earnings and a favorable obesity drug pricing deal with the U.S. government. However, this recent success doesn...
IBM's Quantum Push Intensifies, LLY Price Target Hike, ONON Soars 20% on Earnings
ON Holding (ONON) jumped higher with an earnings beat and guidance raise giving shares a platform to rally. Diane King Hall points to sales doubling in the Asia-Pacific region as a big catalyst.
Cramer's Mad Dash: Eli Lilly
Jim Cramer breaks down why he's keeping an eye on shares of Eli Lilly.
Eli Lilly drops CVS drug plan for workers after Novo obesity deal, Bloomberg News reports
Eli Lilly is dropping CVS Health's drug benefit plan for its employees after CVS stopped covering its weight-loss drug in favor of a rival medication from Novo Nordisk , Bloomberg News reported on Tue...
Why cutting drug prices is pushing Eli Lilly's stock toward an all-time high
Even by dramatically lowering the prices of some of its medications, the drug giant is still outpacing its rivals and nearing a trillion-dollar valuation.
GLP-1 prices are dropping: Who exactly will benefit?
CNBC's Bertha Coombs asks President Trump and his team at the White House's announcement on lower prices for Eli Lilly and Novo Nordisk's GLP-1 medications, if those new prices will extend to commerci...